JPH11512414A - エリスロポエチン及び鉄剤を含有する医薬配合製剤 - Google Patents
エリスロポエチン及び鉄剤を含有する医薬配合製剤Info
- Publication number
- JPH11512414A JPH11512414A JP9511661A JP51166197A JPH11512414A JP H11512414 A JPH11512414 A JP H11512414A JP 9511661 A JP9511661 A JP 9511661A JP 51166197 A JP51166197 A JP 51166197A JP H11512414 A JPH11512414 A JP H11512414A
- Authority
- JP
- Japan
- Prior art keywords
- iron
- epo
- ferritin
- combination preparation
- transferrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims description 320
- 229910052742 iron Inorganic materials 0.000 title claims description 172
- 239000003795 chemical substances by application Substances 0.000 title claims description 26
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract description 51
- 102000003951 Erythropoietin Human genes 0.000 title abstract description 7
- 108090000394 Erythropoietin Proteins 0.000 title abstract description 7
- 229940105423 erythropoietin Drugs 0.000 title abstract description 7
- 208000007502 anemia Diseases 0.000 claims abstract description 30
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000001631 haemodialysis Methods 0.000 claims abstract description 22
- 230000000322 hemodialysis Effects 0.000 claims abstract description 22
- 239000002552 dosage form Substances 0.000 claims abstract description 18
- 102000008857 Ferritin Human genes 0.000 claims description 63
- 108050000784 Ferritin Proteins 0.000 claims description 61
- 238000008416 Ferritin Methods 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 48
- 238000009472 formulation Methods 0.000 claims description 40
- 102000004338 Transferrin Human genes 0.000 claims description 39
- 108090000901 Transferrin Proteins 0.000 claims description 39
- 239000012581 transferrin Substances 0.000 claims description 39
- 238000011282 treatment Methods 0.000 claims description 35
- 102000007238 Transferrin Receptors Human genes 0.000 claims description 26
- 108010033576 Transferrin Receptors Proteins 0.000 claims description 25
- -1 iron ion Chemical class 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 13
- 229940082629 iron antianemic preparations Drugs 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 238000012856 packing Methods 0.000 claims description 7
- 238000011260 co-administration Methods 0.000 claims description 6
- 239000003978 infusion fluid Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 claims description 4
- 235000020796 iron status Nutrition 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 108010046015 ferritin receptor Proteins 0.000 claims description 2
- 229940050410 gluconate Drugs 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 abstract description 3
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 abstract description 3
- 102000044890 human EPO Human genes 0.000 abstract description 3
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 44
- 102100031939 Erythropoietin Human genes 0.000 description 44
- 210000002966 serum Anatomy 0.000 description 20
- 210000003743 erythrocyte Anatomy 0.000 description 18
- 150000004698 iron complex Chemical class 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 102100032752 C-reactive protein Human genes 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 9
- 239000003708 ampul Substances 0.000 description 9
- 238000012937 correction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 238000012423 maintenance Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 8
- 206010022971 Iron Deficiencies Diseases 0.000 description 8
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 208000017667 Chronic Disease Diseases 0.000 description 6
- 230000009469 supplementation Effects 0.000 description 6
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 231100000572 poisoning Toxicity 0.000 description 5
- 230000000607 poisoning effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010001497 Agitation Diseases 0.000 description 4
- CZNVSLGYWMSMKE-OPDGVEILSA-K Ferric gluconate Chemical group [Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CZNVSLGYWMSMKE-OPDGVEILSA-K 0.000 description 4
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 4
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000010437 erythropoiesis Effects 0.000 description 4
- 230000010438 iron metabolism Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000001995 reticulocyte Anatomy 0.000 description 4
- 206010048998 Acute phase reaction Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010065973 Iron Overload Diseases 0.000 description 3
- 206010024264 Lethargy Diseases 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000013583 drug formulation Substances 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 150000002505 iron Chemical class 0.000 description 3
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 3
- 230000009103 reabsorption Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000018565 Hemochromatosis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004658 acute-phase response Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- VAMMNAAZSNNEDJ-UHFFFAOYSA-N butanedioic acid;iron Chemical compound [Fe].OC(=O)CCC(O)=O VAMMNAAZSNNEDJ-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- IMWCPTKSESEZCL-SPSNFJOYSA-H (e)-but-2-enedioate;iron(3+) Chemical compound [Fe+3].[Fe+3].[O-]C(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O IMWCPTKSESEZCL-SPSNFJOYSA-H 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 1
- 206010017866 Gastritis haemorrhagic Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010017480 Hemosiderin Proteins 0.000 description 1
- 208000028958 Hyperferritinemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000016286 Iron metabolism disease Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- BLSARLHSHJTCIK-WTCAGTSSSA-H OC(C([O-])=O)(O)[C@@H](O)[C@H](O)[C@H](O)C(=O)[O-].[Fe+3].OC(C([O-])=O)(O)[C@@H](O)[C@H](O)[C@H](O)C(=O)[O-].OC(C([O-])=O)(O)[C@@H](O)[C@H](O)[C@H](O)C(=O)[O-].[Fe+3] Chemical compound OC(C([O-])=O)(O)[C@@H](O)[C@H](O)[C@H](O)C(=O)[O-].[Fe+3].OC(C([O-])=O)(O)[C@@H](O)[C@H](O)[C@H](O)C(=O)[O-].OC(C([O-])=O)(O)[C@@H](O)[C@H](O)[C@H](O)C(=O)[O-].[Fe+3] BLSARLHSHJTCIK-WTCAGTSSSA-H 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- MSNWSDPPULHLDL-UHFFFAOYSA-K ferric hydroxide Chemical compound [OH-].[OH-].[OH-].[Fe+3] MSNWSDPPULHLDL-UHFFFAOYSA-K 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- VAVPGQSSOJBZIP-UHFFFAOYSA-N sodium;iron(3+) Chemical compound [Na+].[Fe+3] VAVPGQSSOJBZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MYVIATVLJGTBFV-UHFFFAOYSA-M thiamine(1+) chloride Chemical compound [Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N MYVIATVLJGTBFV-UHFFFAOYSA-M 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- GZXOHHPYODFEGO-UHFFFAOYSA-N triglycine sulfate Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.OS(O)(=O)=O GZXOHHPYODFEGO-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- FUTVBRXUIKZACV-UHFFFAOYSA-J zinc;3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate Chemical compound [Zn+2].[N-]1C2=C(C)C(CCC([O-])=O)=C1C=C([N-]1)C(CCC([O-])=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 FUTVBRXUIKZACV-UHFFFAOYSA-J 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 2000〜7000UのEPOと、1〜20mgの鉄イオンと等価の生 理学的に耐え得る鉄剤とを含有してなる医薬配合製剤。 2. 3000〜7000UのEPOと5〜20mgの鉄イオンとを含有する ことを特徴とする請求項1記載の配合製剤。 3. 5000UのEPOと10mgの鉄イオンとを含有することを特徴とす る請求項1又は2記載の配合製剤。 4. 2000〜4000UのEPOと3〜10mgの鉄イオンとを含有する ことを特徴とする請求項1記載の配合製剤。 5. 3000UのEPOと5mgの鉄イオンとを含有することを特徴とする 請求項4記載の配合製剤。 6. 鉄剤が30000〜100000Dの分子量を有する複合体(Komplex )、好ましくはFe(III)サッカラートであることを特徴とする、請求項1 〜5いずれか記載の配合製剤。 7. 鉄剤がFe(III)グルコネートであることを特徴とする、請求項1 〜5いずれか記載の配合製剤。 8. 血液透析患者の治療のための、請求項1〜3、6又は7いずれか記載の 配合製剤。 9. 貧血の治療のための、請求項1又は4〜7いずれか記載の配合製剤。 10. 2000〜7000UのrhEPOと、1〜20mgの鉄イオンと等価 の生理学的に耐え得る鉄剤とを製薬的に通常の担体又はアジュバントと共に調剤 し、そしてそれぞれの製剤を配合製剤の形態として供給することを特徴とする、 請求項1〜9いずれか記載の医薬配合製剤の製造方法。 11. 血液透析患者の治療のために、1〜20mgの鉄イオンと等価の生理学 的に耐え得る鉄剤と共に併用投与するための、2000〜7000UのEPOを 含有する配合製剤の製造におけるEPOの使用。 12. 貧血の治療のために、3〜10mgの鉄イオンと等価の生理学的に耐え 得る鉄剤と共に併用投与するための、2000〜4000UのEPOを含有する 配合製剤の製造におけるEPOの使用。 13. 一つの容器内での統合的な投与形態として、又は別々の容器内での個別 的な投与形態として、2000〜7000UのEPOと、1〜20mgの鉄イオ ンと等価の生理学的に耐え得る鉄剤とを含有してなる薬剤パッキングユニット。 14. EPOと鉄剤それぞれが、注射用及び/又は点滴用溶液として、又は凍 結乾燥物として個別的な投与形態で存在することを特徴とする、請求項13記載 のパッキングユニット。 15. EPOと鉄剤それぞれが、注射用及び/又は点滴用溶液として、又は凍 結乾燥物として統合的な投与形態で存在することを特徴とする、請求項13記載 のパッキングユニット。 16. 第一工程において、トランスフェリンの飽和度だけでなく、鉄、トラン スフェリン及びフェリチンの濃度を、そして第二工程においてトランスフェリン /フェリチンの飽和度を測定する、体液試料における鉄の状態を測定する方法。 17. 血液透析患者の鉄の状態を測定するための請求項16記載の方法。 18. 第一工程において、フェリチン及びトランスフェリンレセプター(Tf R)の濃度を、そして第二工程においてトランスフェリンレセプター/フェリチ ンの飽和度を測定する、体液試料における鉄の状態を測定する方法。 19. 貧血患者の鉄の状態を測定するための請求項18記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19535571A DE19535571A1 (de) | 1995-09-14 | 1995-09-14 | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
DE19535571.7 | 1995-09-14 | ||
PCT/EP1996/003997 WO1997009996A1 (de) | 1995-09-14 | 1996-09-12 | Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11512414A true JPH11512414A (ja) | 1999-10-26 |
JP4783482B2 JP4783482B2 (ja) | 2011-09-28 |
Family
ID=7773098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51166197A Expired - Lifetime JP4783482B2 (ja) | 1995-09-14 | 1996-09-12 | エリスロポエチン及び鉄剤を含有する医薬配合製剤 |
Country Status (26)
Country | Link |
---|---|
US (2) | US6333306B1 (ja) |
EP (1) | EP0851762B1 (ja) |
JP (1) | JP4783482B2 (ja) |
KR (1) | KR100350761B1 (ja) |
CN (1) | CN1133463C (ja) |
AT (1) | ATE216256T1 (ja) |
AU (1) | AU724623B2 (ja) |
BR (1) | BR9609971A (ja) |
CA (1) | CA2231192C (ja) |
CZ (1) | CZ291427B6 (ja) |
DE (3) | DE19535571A1 (ja) |
DK (1) | DK0851762T3 (ja) |
EE (1) | EE03856B1 (ja) |
ES (1) | ES2174107T3 (ja) |
HU (1) | HU225363B1 (ja) |
IL (2) | IL123640A0 (ja) |
MX (1) | MX9801922A (ja) |
NO (1) | NO329908B1 (ja) |
NZ (1) | NZ319132A (ja) |
PL (1) | PL186776B1 (ja) |
PT (1) | PT851762E (ja) |
SK (1) | SK285796B6 (ja) |
TR (1) | TR199800472T1 (ja) |
UA (1) | UA57713C2 (ja) |
WO (1) | WO1997009996A1 (ja) |
ZA (1) | ZA967732B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009510402A (ja) * | 2005-09-24 | 2009-03-12 | ベックマン コールター, インコーポレイテッド | エリスロポエチン治療に対する反応性の決定法 |
JP2016521747A (ja) * | 2013-06-13 | 2016-07-25 | アケビア セラピューティクス インコーポレイテッドAkebia Therapeutics Inc. | 貧血治療のための組成物及び方法 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ337465A (en) * | 1997-03-18 | 2002-04-26 | Roche Diagnostics Gmbh | Pharmaceutical containing erythropoietin and iron preparations for treating haemodialysis patients or anaemias |
EP0885613A1 (de) * | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
DE19734293A1 (de) | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
US7304150B1 (en) | 1998-10-23 | 2007-12-04 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
AR020848A1 (es) * | 1998-10-23 | 2002-05-29 | Amgen Inc | Metodos y composiciones para la prevencion y el tratamiento de anemia |
BR0116381A (pt) | 2000-12-20 | 2004-02-25 | Hoffmann La Roche | Conjugado, composição farmacêutica que compreende o mesmo e sua utilização, processo para o tratamento profilático e/ou terapêutico de distúrbios, processo para a preparação de um conjugado, compostos e glicoproteìnas de eritropoetina |
EP1909106B1 (en) * | 2001-09-14 | 2013-01-02 | F. Hoffmann-La Roche AG | Differential diagnosis of disorders of iron metabolism by means of four parameters and recommendations for the treatment of these disorders of iron metabolism |
US6930086B2 (en) | 2001-09-25 | 2005-08-16 | Hoffmann-La Roche Inc. | Diglycosylated erythropoietin |
US7300915B2 (en) * | 2002-06-05 | 2007-11-27 | The Regents Of The University Of California | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
US7459435B2 (en) * | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
US7459436B2 (en) * | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
US7964568B2 (en) * | 2003-05-30 | 2011-06-21 | Chromaceutical Advanced Technologies, Inc. | Synthesis of high molecular weight iron-saccharidic complexes |
US7772182B2 (en) * | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
JP5723528B2 (ja) | 2006-08-04 | 2015-05-27 | プロロング ファーマシューティカルズ エルエルシー | 修飾されたエリスロポエチン |
CL2008002054A1 (es) | 2007-07-17 | 2009-05-29 | Hoffmann La Roche | Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico. |
CL2008002053A1 (es) * | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
SI3380487T1 (sl) | 2015-11-23 | 2020-11-30 | Bristol-Myers Squibb Company | Sistemi dodatkov za uporabo pri pegilaciji proteinov |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5283905A (en) * | 1976-01-01 | 1977-07-13 | Nippon Zoki Pharmaceutical Co | Production of dextrin hydroxycarboxylic acid and ferric multinuclear complex |
JPS6231A (ja) * | 1985-02-06 | 1987-01-06 | Chugai Pharmaceut Co Ltd | 腎性貧血治療剤 |
JPS63277630A (ja) * | 1987-04-10 | 1988-11-15 | オーソ・フアーマシユーチカル・コーポレーシヨン | 正常な哺乳動物のヘマトクリツト値の増大方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin |
US4745099A (en) * | 1985-02-06 | 1988-05-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of malignant tumors |
-
1995
- 1995-09-14 DE DE19535571A patent/DE19535571A1/de not_active Withdrawn
-
1996
- 1996-09-12 US US09/029,859 patent/US6333306B1/en not_active Expired - Lifetime
- 1996-09-12 ES ES96932503T patent/ES2174107T3/es not_active Expired - Lifetime
- 1996-09-12 DK DK96932503T patent/DK0851762T3/da active
- 1996-09-12 CA CA002231192A patent/CA2231192C/en not_active Expired - Lifetime
- 1996-09-12 HU HU9900357A patent/HU225363B1/hu unknown
- 1996-09-12 CN CNB961982845A patent/CN1133463C/zh not_active Expired - Lifetime
- 1996-09-12 DE DE19680768T patent/DE19680768D2/de not_active Expired - Lifetime
- 1996-09-12 SK SK327-98A patent/SK285796B6/sk not_active IP Right Cessation
- 1996-09-12 AT AT96932503T patent/ATE216256T1/de active
- 1996-09-12 NZ NZ319132A patent/NZ319132A/en not_active IP Right Cessation
- 1996-09-12 BR BR9609971-2A patent/BR9609971A/pt not_active Application Discontinuation
- 1996-09-12 CZ CZ1998726A patent/CZ291427B6/cs not_active IP Right Cessation
- 1996-09-12 IL IL12364096A patent/IL123640A0/xx active IP Right Grant
- 1996-09-12 PT PT96932503T patent/PT851762E/pt unknown
- 1996-09-12 PL PL96325640A patent/PL186776B1/pl unknown
- 1996-09-12 DE DE59609099T patent/DE59609099D1/de not_active Expired - Lifetime
- 1996-09-12 EE EE9800066A patent/EE03856B1/xx unknown
- 1996-09-12 WO PCT/EP1996/003997 patent/WO1997009996A1/de active IP Right Grant
- 1996-09-12 KR KR10-1998-0701860A patent/KR100350761B1/ko not_active IP Right Cessation
- 1996-09-12 JP JP51166197A patent/JP4783482B2/ja not_active Expired - Lifetime
- 1996-09-12 MX MX9801922A patent/MX9801922A/es unknown
- 1996-09-12 AU AU71282/96A patent/AU724623B2/en not_active Expired
- 1996-09-12 TR TR1998/00472T patent/TR199800472T1/xx unknown
- 1996-09-12 EP EP96932503A patent/EP0851762B1/de not_active Expired - Lifetime
- 1996-09-13 ZA ZA9607732A patent/ZA967732B/xx unknown
- 1996-12-09 UA UA98041874A patent/UA57713C2/uk unknown
-
1998
- 1998-03-11 IL IL123640A patent/IL123640A/en not_active IP Right Cessation
- 1998-03-13 NO NO19981136A patent/NO329908B1/no not_active IP Right Cessation
-
2001
- 2001-10-29 US US09/984,268 patent/US20020049161A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5283905A (en) * | 1976-01-01 | 1977-07-13 | Nippon Zoki Pharmaceutical Co | Production of dextrin hydroxycarboxylic acid and ferric multinuclear complex |
JPS6231A (ja) * | 1985-02-06 | 1987-01-06 | Chugai Pharmaceut Co Ltd | 腎性貧血治療剤 |
JPS63277630A (ja) * | 1987-04-10 | 1988-11-15 | オーソ・フアーマシユーチカル・コーポレーシヨン | 正常な哺乳動物のヘマトクリツト値の増大方法 |
Non-Patent Citations (1)
Title |
---|
JPN4007021886, 日本臨床 血液浄化療法 上巻, 19911218, 日本臨床49巻, 1991年増刊号, pp.670−678, JP, 株式会社日本臨床社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009510402A (ja) * | 2005-09-24 | 2009-03-12 | ベックマン コールター, インコーポレイテッド | エリスロポエチン治療に対する反応性の決定法 |
JP2016521747A (ja) * | 2013-06-13 | 2016-07-25 | アケビア セラピューティクス インコーポレイテッドAkebia Therapeutics Inc. | 貧血治療のための組成物及び方法 |
JP2019163293A (ja) * | 2013-06-13 | 2019-09-26 | アケビア セラピューティクス インコーポレイテッドAkebia Therapeutics Inc. | 貧血治療のための組成物及び方法 |
JP2021191773A (ja) * | 2013-06-13 | 2021-12-16 | アケビア セラピューティクス インコーポレイテッドAkebia Therapeutics Inc. | 貧血治療のための組成物及び方法 |
US11857543B2 (en) | 2013-06-13 | 2024-01-02 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4783482B2 (ja) | エリスロポエチン及び鉄剤を含有する医薬配合製剤 | |
US6372715B1 (en) | Use of erythropoientin and iron preparations for producing pharmaceutical combination preparations for treating rheumatic diseases | |
CA2284910C (en) | Pharmaceutical combined preparations containing erythropoietin and iron preparations | |
EP1085900B1 (en) | Use of erythropoietin for the treatment of primary haemochromatoses | |
RU2188033C2 (ru) | Комбинированные фармацевтические препараты, содержащие эритропоэтин и препараты железа | |
RU2173168C2 (ru) | Фармацевтические комбинированные препараты, содержащие эритропоэтин и препараты железа | |
MXPA99008451A (en) | Pharmaceutical combined preparations containing erythropoietin and iron preparations | |
KR20000076259A (ko) | 에리트로포이에틴과 철 제제를 포함하는 약학 조합제제 | |
CN1248920A (zh) | 含***和铁制剂的药物联合制剂 | |
MXPA00001172A (en) | The use of erythropoietin and iron preparations for producing pharmaceutical combination preparations for treating rheumatic diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060613 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060821 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071009 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080107 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080324 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080307 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080718 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20081016 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20081120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090608 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090611 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110119 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110128 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110222 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110302 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110328 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110405 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110428 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110711 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140715 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |